whitepaper

Whitepaper: iPSC manufacturing for drug discovery

Posted: 13 July 2020 | | No comments yet

Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.

The lack of physiologically-relevant cell-based assays is an obstacle in drug development. Introducing human disease biology early in drug development could make it more effective. However, human primary tissues are rarely available in quantities sufficient for HTS. Although hiPSCs are suitable for disease modeling, the challenge of industrial scale manufacturing from different hiPSC sources has long remained. Here we describe how we enabled the production of batches of billions of cells.











To read this whitepaper in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Ncardia

Related organisations

Send this to a friend